Hematological and infectious complications with CD38 antigen targeting monoclonal antibody-based therapies in multiple myeloma: A meta-analysis of randomized control trials

Leuk Res. 2021 Nov:110:106714. doi: 10.1016/j.leukres.2021.106714. Epub 2021 Sep 25.

Authors

Naveen Yarlagadda¹, Sravani Gundarlapalli¹, Smriti Sharma², Elizabeth Suelzer³, Muhammad Bilal Abid³, Al-Ola Abdallah⁴, Carolina Schinke¹, Shebli Atrash⁵, Meera Mohan⁶

Affiliations

¹ University of Arkansas for Medical Sciences, Little Rock, AR, United States.
² Unversity of Nebraska Medical Center, Omaha, NE, United States.
³ Medical College of Wisconsin, Milwaukee, WI, United States.
⁴ University of Kansas Medical Center, United States.
⁵ Atrium Health Levine Cancer Institute, NC, United States.
⁶ Medical College of Wisconsin, Milwaukee, WI, United States. Electronic address: memohan@mcw.edu.

PMID: 34598075
DOI: 10.1016/j.leukres.2021.106714

No abstract available

Publication types

Letter
Meta-Analysis

MeSH terms

ADP-ribosyl Cyclase 1 / antagonists & inhibitors*
Antibodies, Monoclonal / adverse effects*
Communicable Diseases / chemically induced
Communicable Diseases / pathology*
Hematologic Diseases / chemically induced
Hematologic Diseases / pathology*
Humans
Multiple Myeloma / drug therapy*
Multiple Myeloma / pathology
Prognosis
Randomized Controlled Trials as Topic

Substances

Antibodies, Monoclonal
ADP-ribosyl Cyclase 1